Actively Recruiting
BAI-BACE for Advanced Lung Squamous Cell Carcinoma
Led by Sun Yat-sen University · Updated on 2024-08-09
85
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Bronchial arterial infusion plus bronchial arterial chemoembolization (BAI-BACE) has been reported as non-first-line therapy to treat lung cancer in many hospitals in China. BAI, which uses chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor. Then BACE could seal off the tumor vessels. In this study, we aim to describe the efficacy and safety of BAI-BACE as non-first-line for advanced lung squamous cell carcinoma.
CONDITIONS
Official Title
BAI-BACE for Advanced Lung Squamous Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with central squamous cell carcinoma by pathology and imaging
- Age between 18 and 80 years
- Have failed standard first-line or second-line treatment
- Tumors limited to the chest area
- Tumors supplied by bronchial artery confirmed by CTA reconstruction
- Patients treated with or without PD-1 inhibitors are eligible
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2
- Imaging done within 2 weeks before enrollment
- Life expectancy longer than 3 months
- Agree to participate in this clinical trial
- Adequate blood counts and liver, kidney function within defined limits
You will not qualify if you...
- Contraindications to bronchial arterial infusion or chemoembolization
- Under 18 years or over 75 years of age
- Presence of metastases outside the chest
- Currently receiving other antitumor treatments
- Severe infection or pregnancy
- Severe pulmonary fibrosis or pulmonary artery disease
- Poor liver, kidney function or poor physical condition
- Severe pleural effusion or pericardial effusion
- Life expectancy less than 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA General hospital
Beijing, Beijing Municipality, China, 100853
Actively Recruiting
Research Team
Q
Qunfang Zhou, MD
CONTACT
F
Feng Duan, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here